6317-59-5

Usage

Uses

Used in Pharmaceutical Industry:
[4-(phenylsulfanyl)phenyl]acetonitrile is utilized as a key intermediate in the synthesis of a wide array of biologically active compounds. Its unique structure and reactivity make it an indispensable component in the development of new pharmaceutical agents, targeting various medical conditions and diseases.
Used in Agrochemical Industry:
Within the agrochemical sector, [4-(phenylsulfanyl)phenyl]acetonitrile is employed as a vital building block for the creation of novel agrochemicals. Its application in this industry is primarily focused on the development of new pesticides, herbicides, and other agricultural chemicals that can enhance crop protection and yield.
Used as an Anti-Inflammatory Agent:
[4-(phenylsulfanyl)phenyl]acetonitrile has been studied for its potential as an anti-inflammatory agent. Its unique chemical structure allows it to modulate inflammatory pathways, offering a promising avenue for the development of new anti-inflammatory drugs to treat various inflammatory conditions.
Used as an Antimicrobial Agent:
Additionally, [4-(phenylsulfanyl)phenyl]acetonitrile has shown potential as an antimicrobial agent. Its ability to combat microbial infections makes it a valuable candidate for the development of new antimicrobial drugs, addressing the growing need for novel antibiotics and antifungal agents in the face of increasing antibiotic resistance.

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 930-69-8 sodium thiophenolate 
• 1208-87-3 1-phenylthio-4-chloromethyl-benzene 
• 6317-56-2 4-hydroxymethylphenyl phenyl sulfide 
• 1208-88-4 4-phenylsulfanyl-benzaldehyde 
• 898535-26-7 methanesulfonic acid 4-phenylsulfanyl-benzyl ester 
• 143-33-9 sodium cyanide 

Downstream Products

• 72141-37-8 2-(4-benzenesulfinyl-phenyl)-2-imidazol-1-ylmethyl-hexanenitrile 
• 72141-35-6 2-imidazol-1-ylmethyl-2-(4-phenylsulfanyl-phenyl)-hexanenitrile 
• 142664-09-3 3-amino-4-(4-phenylthio)phenylpyrazole 
• 85554-28-5 (4-benzenesulfonyl-phenyl)-acetonitrile 
• 6317-61-9 (4-phenylsulfanyl-phenyl)-acetic acid 

Relevant academic research and scientific papers

Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors

Various sulfonyl-containing compounds (e.g. sulfonamides, sulfones) bind at human 5-HT6 serotonin receptors, but it has been difficult relating the binding mode(s) of such agents to one another, even though many possess a common SO2 moiety, to identify a common pharmacophore model(s). On the basis of the hypothesis that an ergoline-type conformation might be important for the binding of some sulfonamide-containing arylalkylamines, we prepared for examination at h5-HT6 receptors a series of compounds, including phenylethylamines 6, pyrroloethylamine 7, and phenylpiperazines 9. The results (with Ki values ranging from about 1 nM to > 1000 nM) suggest that many of these agents likely bind in a related fashion, and structure-affinity studies indicate that the benzenesulfonamide portion of the phenylethylamine and phenylpiperazine analogues can be "reversed", abbreviated to a sulfone, and moved to an adjacent position with relatively little impact on affinity. Although a benzenesulfonamide (or related arylsulfonamide) group might be common to various 5-HT6 ligands, there appears to be some latitude with regard to the specific constitution and location of the sulfonamide moiety even within the same arylalkylamine structural framework. A pharmacophore model is presented to account for some of the current findings.

Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor

The invention discloses a pyrimidien derivative expressed in Formula [I]: STR1 where R 1 denotes a hydrogen atom or hydroxyl group, R 2 denotes a hydrogen atom, lower alkoxycarbonyl group, lower alkoxy group, halogen atom, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, lower alkoxycarbonyl lower alkyl group, carboxyl group, carboxy lower alkyl group, group: --CONHR 6 (R 6 represents a hydrogen atom, a phenyl group, which may possess halogen atom, or lower alkyl group), cyano group, phenyl group which may possess a group selected from the group consisting of hydroxyl group, halogen atom, lower alkyl group, lower alkoxy group and phenylthio group as a substituent, phenyl lower alkyl group which may possess a group selected from the group consisting of hydroxyl group and lower alkoxy group as a substituent on a phenyl ring, lower alkanoyloxy lower alkyl group, benzoyl group, lower alkanoyl group which may possess a halogen atom, or hydroxy lower alkyl group which may possess a group selected from the group consisting of phenyl group and halogen atom as a substituent, R 3 denotes a hydrogen atom, hydroxyl group, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, halogen lower alkyl group, or phenyl group, R 4 denotes a hydrogen atom, lower alkyl group, or lower alkoxy group, and R 5 denotes a hydrogen atom, lower alkyl group, lower alkoxy lower alkyl group, or halogen lower alkyl group; provided that R 2 and R 3 may be bonded to each other to form a lower alkylene group with 3 to 5 carbon atoms, or its pharmaceutically available salt. This derivative is excellent in therapeutic effects of benign prostatic hypertrophy, prostatic carcinoma, female hairiness, male baldness or pimple as an androgen inhibitor.

CARBONYLATION OF p-HALOGENOBENZYL CYANIDES IN THE PRESENCE OF COBALT OCTACARBONYL. TEST FOR RADICAL-ANION MECHANISM

In the reaction of p-halogenobenzyl cyanides with sodium thiophenolate under the conditions of an SRN1 reaction the intermediately formed radical-anion undergoes fragmentation in two concurrent directions, i.e., with elimination of the cyanide ion and with elimination of the halide ion.The presence of the two fragmentation paths was used as evidence for the radical-anion nature of the intermediates in the carbonylation of aryl halides.

Pyrazolotriazine compounds

Pyrazolotriazine compounds of the formula: STR1 wherein R1 is OH or alkanoyloxy; R2 is H, OH, or SH; R3 is (1) unsaturated N- or S-containing heterocyclic group optionally having 1-2 substituents of halogen, nitro or phenylthio, (2) naphthyl, (3) phenyl optionally having 1-3 substituents of (i) alkyl, (ii) phenyl, (iii) alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) alkoxy, (vii) phenylalkoxy (viii) phenylthio-alkyl, (ix) phenoxy, (x) STR2 R is alkyl, halo-substituted alkyl, phenyl optionally having 1-3 substituents, or pyridyl, and l is 0, 1 or 2, (xi) halogen, (xii) phenylalkyl, (xiii) carboxy, (xiv) alkanoyl, (xv) benzoyl optionally having 1-3 substituents, (xvi) amino, (xvii) OH, (xviii) alkanoyloxy, (xix) STR3 or (xx) STR4 (A is alkylene), said compounds having a xanthine oxidase inhibitory activity and are useful for the prophylaxis and treatment of gout.

Cyanoaralkylheterocyclic compounds

This invention relates to phenoxy, phenylthio, phenylsulfinyl and phenylsulfonyl substituted cyano aralkyl imidazoles and triazoles, their enantiomorphs, acid addition salts and metal salt complexes thereof as well as their methods of preparation and use